 |
|
A new molecular marker of gastric cancer
March 31, 2009Gastric cancer (GC) is one of the most common malignancies in the world with a high incidence and death rate. TNM staging system is used worldwide to predict prognosis and direct therapeutic decisions of patients with GC. However, the prognoses of patients with stage 2 and 3 GC are more heterogeneous and less predictable by staging criteria. Therefore, finding molecular markers that are able to predict the potential of tumor recurrence and prognosis of patients is extremely important for appropriate individualized therapy. Phosphatase regenerating liver 3 (PRL-3), a member of phosphotase of regenerating liver, has aroused broad attention in the research area of tumor metastasis. A growing body of evidence has proved PRL-3 to be an important metastatic instrumental molecule. In gastric cancer, PRL-3 was found to be highly expressed in tumor metastatic lymph nodes and closely associated with the peritoneal metastasis, but the prognostic impact of PRL-3 expression in gastric cancer still remains to be further investigated.
A research team led by Dr. Ji-You Li from Peking University University addressed this issue and their study will be published on March 28, 2009 in the World Journal of Gastroenterology.
In their study, PRL-3 expression in paraffin-embedded tumor specimens from 293 patients with gastric cancer was studied retrospectively by immunohistochemistry. Monoclonal antibody specifically against PRL-3, 3B6, was obtained with hybridoma technique.
Positive PRL-3 expression was detected in 43.3% (127 of 293) of gastric cancer cases. High expression of PRL-3 was positively correlated with tumor size, depth of invasion, vascular/lymphatic invasion, lymph node metastasis, high TNM stage and tumor recurrence. Patients with positive PRL-3 expression had a significantly lower 5-year survival rate than those with negative expression (28.3% vs 51.9%, P < 0.0001). Patients who received curative surgery, and with positive PRL-3 expression had a significant shorter overall survival and disease-free disadvantage over patients with negative expression (hazard ratio of 16.7 and 16.6, respectively; P < 0.0001 for both). Multivariate analysis revealed that PRL-3 expression was an independent prognostic indicator for overall and disease-free survival of gastric cancer patients, particularly for survival in TNM stage 3 patients.
Their result indicated that PRL-3 expression is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection.
World Journal of Gastroenterology
Positive PRL-3 expression was detected in 43.3% (127 of 293) of gastric cancer cases. High expression of PRL-3 was positively correlated with tumor size, depth of invasion, vascular/lymphatic invasion, lymph node metastasis, high TNM stage and tumor recurrence. Patients with positive PRL-3 expression had a significantly lower 5-year survival rate than those with negative expression (28.3% vs 51.9%, P < 0.0001). Patients who received curative surgery, and with positive PRL-3 expression had a significant shorter overall survival and disease-free disadvantage over patients with negative expression (hazard ratio of 16.7 and 16.6, respectively; P < 0.0001 for both). Multivariate analysis revealed that PRL-3 expression was an independent prognostic indicator for overall and disease-free survival of gastric cancer patients, particularly for survival in TNM stage 3 patients.
Their result indicated that PRL-3 expression is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection.
World Journal of Gastroenterology
Gastric Cancer Current Events and Gastric Cancer News RSSAfrican-Americans with colorectal cancer have poorer outcomes, lower survival rates
New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.
Is short-term Celecoxib intervention a effective method for preventing gastric carcinogenesis?
Since the isolation and culture of Helicobacter pylori (H. pylori) in 1983, this bacterium has become accepted as an important human pathogen for the development of gastritis, peptic ulcer, and gastric cancer.
A new explanation of 'Asian paradox'
Although Helicobacter pylori (H. pylori) has been classified as a class I (or definite) carcinogen by World Health Organization (WHO), the controversy as to why only a minority of infected patients develop gastric cancer still remains.
Will genomics help prevent the next pandemic?
This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.
Protein interaction network can respond Helicobacter pylori infection?
Helicobacter pylori (H pylori) is a gram negative bacterium which infects about 50% of the world population. H pylori colonization causes a strong systemic immune response.
A case of post-gastrectomy acute pancreatitis
Gastrectomy is commonly performed for both benign and malignant lesions. Although the incidence of post-gastrectomy acute pancreatitis (PGAP) is low compared to other well-recognized post-operative complications, it has been reported to be associated with a high mortality rate.
Does Helicobacter pylori eradication therapy prevent gastric cancer?
Although it has been demonstrated that Helicobacter pylori causes gastric cancer, it is still controversial that whether H. pylori eradication therapy is effective in primary prevention of gastric cancer.
New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers
Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress.
NIH study reveals new genetic culprit in deadly skin cancer
Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma.
PPAR-g agonists have potential therapeutic role in gastric carcinoma?
Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied.
More Gastric Cancer Current Events and Gastric Cancer News Articles
 |
100 Q&A About Gastric Cancer (100 Questions & Answers about . . .) (100 Questions and Answers) by Manish A. Shah (Author) About 21,700 Americans are diagnosed with stomach cancer each year and it occurs most often in people in their 60s and 70s. Whether you're a newly diagnosed patient with gastric cancer or a friend or relative of someone with cancer, this book offers help. This book is an invaluable resource for anyone coping with the physical and emotional turmoil of this disease. The author Dr. Shah is from Memorial Sloan-Kettering Cancer Center, one of the few National Cancer Institute-designated cancer centers with a specific program in treating cancers of the upper gastrointestinal tract and has made many of the major advances in the treatment of these diseases. |
 |
Cancer Of The Stomach, A Clinical Study Of 921 Operatively And Pathologically Demonstrated Cases: With A Chapter On The Surgical Treatment Of Gastric Cancer by Frank Smithies (Author), Albert John Ochsner (Contributor) This scarce antiquarian book is included in our special Legacy Reprint Series. In the interest of creating a more extensive selection of rare historical book reprints, we have chosen to reproduce this title even though it may possibly have occasional imperfections such as missing and blurred pages, missing text, poor pictures, markings, dark backgrounds and other reproduction issues beyond our control. Because this work is culturally important, we have made it available as a part of our commitment to protecting, preserving and promoting the world's literature. |
 |
Gastric Cancer by T. Sugimura (Editor), M. Sasako (Editor) The editors have produced a concise and up-to-date account of all aspects of gastric cancer, which is still one of the five major causes of cancer death in most countries of the world today. The book ranges from epidemiology, aetiology, and biology, to surgical and non-surgical treatements and primary and secondary prevention. It summarizes the latest progress in the various fields, as well as providing practical guidance on diagnosis and management, and is written by acknowledged experts in the subject both in the West and Japan. |
 |
The Biology of Gastric Cancers by Timothy C. Wang (Editor), James G. Fox (Editor), Andrew S. Giraud (Editor) The purpose of this work is to provide a general and comprehensive reference work on the biology of gastric cancers for those researchers working in this area. This monograph will be written by a panel of experts in each area and represent the latest work in a series of different areas of gastric cancer research. |
 |
The Diversity of Gastric Carcinoma: Pathogenesis, Diagnosis and Therapy by M. Kaminishi (Editor), K. Takubo (Editor), K. Mafune (Editor) Japan has long been a leader of research into the carcinogenesis, pathology, diagnosis, and treatment of gastric carcinoma, which is still the second leading cause of cancer death worldwide. Distinguished experts in the field collaborated in creating this groundbreaking work, providing a comprehensive view of gastric cancer. This book encourages further development of gastric cancer research and its clinical application. Topics include all aspects of gastric carcinoma, such as the history of clinical and experimental gastric cancer research; updated issues of molecular and pathological research on gastric carcinogenesis; multidisciplinary methods in diagnosis, treatment, and chemotherapy; and perspectives in minimally invasive surgery. Color figures of histological specimens and other... |
|
Gastric Cancer by M. Nishi (Author), H. Ichikawa (Author), T. Nakajima (Author), K. Maruyama (Author), E. Tahara (Editor) Cancer Institute Hospital, Tokyo, Japan. Basic science and clinical research on gastric cancer, for oncologists. Includes epidemiology, experimental carcinogenesis, pathology, biology, diagnosis, and treatment. 58 contributors. DNLM: Stomach Neoplasms. | |
|
Multimodality Therapy for Gastric Cancer: Appendix: Database of the Cancer Institute Hospital by Toshifusa Nakajima (Editor), Toshiharu Yamaguchi (Editor), Cancer Institute Hospital (Editor) Recent clinical trials of adjuvant therapy for gastric cancer in Japan have shown improved survival benefits, but the results have been considered controversial and have been viewed with some skepticism in the West. Until now, the efforts of Japanese surgical oncologists in multimodality therapy have not been fully understood because they have not been adequately reported in English. This volume now presents the experience and expertise of Japanese surgeons who utilize preoperative or intraoperative chemotherapy, or a combination of systemic and regional chemotherapy. Their collected work provides valuable insight in the Japanese perspective and success in treating gastric cancer. Included in the appendix is an extensive tabular analysis of the gastric cancer database at the Cancer... | |
|
Early gastric cancer: current status of diagnosis by Springer-Verlag (Publisher) | |
|
Endoscopy in gastric cancer (Recent results in cancer research) by Robert S Nelson (Author) | |
 |
Research Focus on Gastric Cancer by S. M. Abbas (Author), Stefania Boccia (Author), S. Chukov (Author), Domenico D'Ugo (Author), Cecilia Fenoglio-Preiser (Author), Marcelo Galarza (Author), A. Gatopoulou (Author), Giovanni Gazzeri (Author), Francesco Gianfagna (Author), Yuzuru Ikehara (Author), Seiji Ito (Author), S. Kashin (Author), P. Katsinelos (Author), Seigo Kitano (Author), Yasuhiro Kodera (Author), Dorothy C. Cardinni (Editor) This new book presents important leading-edge research on stomach cancer.Stomach cancer (also called gastric cancer ) is the growth of cancer cells in the lining and wall of the stomach. Stomach cancer represents roughly 2% (25,500) cases of all new cancer cases yearly in the United States, but it is much more common in Japan, Great Britain, South America, and Iceland. It is associated with high salt in the diet, smoking, and low intake of fruits and vegetables. Infection with H. pylori is the main risk factor in about 80% or more of gastric cancers. It is more common in men. A very small percentage of diffuse-type gastric cancers are thought to be genetic. Hereditary Diffuse Gastric Cancer (HDGC) has only recently been identified and research is ongoing, but genetic... |
| © 2009 BrightSurf.com |